Reviewer's report

Title: Leptin-induced ER-Positive Breast Cancer Cell Viability and Migration is mediated by Suppressing CCN5-Signaling via Activating JAK/AKT/STAT-pathway

Version: 0 Date: 13 Jun 2017

Reviewer: ABDELKRIM ALILECHE

Reviewer's report:

You are addressing a very complex situation with an inappropriate protocol. Let's start with the technical problems. 1. Factors like Leptin, hrCCN5 should be used as molarity and not as ng/ml. 2. I need to know what is the difference for you between viability and proliferation. You have to chose between MTT or tritiated thymidine uptake. 3. You extend your viability studies to 24h and 48h. However the doubling time for MCF-7 is 29h and the doubling time for ZR-75-1 is 80h. Therefore your viability studies should go to 96h (4 days) to give a chance to both cell lines to grow. Results analysis of Fig1 ABC: I don't se any dramatic effect there, just a simple variation because your conditions are not optimal. As for Fig 2A,B: The effect is not dramatic at all.

Fig2C, I don't see a suppression of apoptosis, your results show some 10-30% decrease. Fig3, the effects are not impressive at all. There is no need for you to explore the effect on EMT or MET. Those results are not credible. You need to repeat the three fig 1,2,3 with a better and adequate protocol.

Your are exploring an important and complex phenomenon.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

'I declare that I have no competing interests'

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal